GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » Total Assets

TFFP (TFF Pharmaceuticals) Total Assets : $7.08 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals Total Assets?

TFF Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $7.08 Mil.

During the past 12 months, TFF Pharmaceuticals's average Total Assets Growth Rate was -13.30% per year. During the past 3 years, the average Total Assets Growth Rate was 24.90% per year. During the past 5 years, the average Total Assets Growth Rate was 108.60% per year.

During the past 7 years, TFF Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 266.70%. The lowest was 24.90%. And the median was 90.20%.

Total Assets is connected with ROA %. TFF Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was -171.12%. Total Assets is also linked to Revenue through Asset Turnover. TFF Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.01.


TFF Pharmaceuticals Total Assets Historical Data

The historical data trend for TFF Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFF Pharmaceuticals Total Assets Chart

TFF Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial 29.19 38.66 40.70 24.12 12.03

TFF Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.89 12.03 9.19 9.50 7.08

TFF Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

TFF Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=9.567+2.46
=12.03

TFF Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=3.137+3.941
=7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TFF Pharmaceuticals  (NAS:TFFP) Total Assets Explanation

Total Assets is connected with ROA %.

TFF Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-14.18/( (9.495+7.078)/ 2 )
=-14.18/8.2865
=-171.12 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

TFF Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0.106/( (9.495+7.078)/ 2 )
=0.106/8.2865
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

TFF Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


TFF Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
Executives
Carlson Capital L P 10 percent owner 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak officer: Chief Medical Officer 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills director 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman officer: CFO, Secretary, and Treasurer 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd 10 percent owner CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts director 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes director, officer: President and CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn director C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc. 10 percent owner P.O. BOX 150183, AUSTIN TX 78715